Neurocrine Biosciences (NBIX) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vaxcyte (PCVX) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 59.9% versus a gain of 4.7%. Over five years, PCVX leads with a +174.3% price change compared with +37.2% for NBIX. Neurocrine Biosciences is the larger company by market cap ($14.58 billion vs $9.96 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBIX | PCVX |
|---|---|---|
| Share price | $143.47 | $66.96 |
| Market cap | $14.58B | $9.96B |
| 1-day change | -1.40% | +0.39% |
| YTD return | +1.16% | +45.12% |
| 1-year return | +4.72% | +59.92% |
| 5-year return | +37.24% | +174.31% |
| P/E ratio (TTM) | 21.04 | — |
| Forward P/E | 12.08 | — |
| EPS (TTM) | $6.82 | $-7.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.86B | — |
| Revenue growth (YoY) | +21.45% | — |
| Net income (latest FY) | $478.60M | $-766.63M |
| Gross margin | 98.18% | — |
| Operating margin | 21.64% | — |
| Net margin | 16.73% | — |
| 52-week high | $186.12 | $90.75 |
| 52-week low | $122.14 | $39.87 |
| Distance from 52-week high | -22.92% | -26.21% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +44.48% | +65.59% |
| Average volume | 1.30M | 1.50M |
| Shares outstanding | 101.65M | 148.81M |
| Employees | 2,500 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCVX has outperformed NBIX by 55.2 percentage points over the past year.
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
NBIX vs PCVX FAQ
Which is bigger, Neurocrine Biosciences or Vaxcyte?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.58B compared with $9.96B for Vaxcyte (PCVX).
Which stock has performed better over the past year, NBIX or PCVX?
PCVX returned +59.92% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Are Neurocrine Biosciences and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.